	_			-	_					_				999 Gly 15		48
		_			_									ttc Phe		96
														tcc Ser		144
								-	-	-	_		_	gta Val		192
			_	_	_		_			_	_		_	gat Asp		240
_			_			_	_		_	_	_			ttc Phe 95	_	288
_		_								_		-		tat Tyr		336
				_			_							Gly 333		384
							_							tcc Ser	_	432
aaa Lys 145	tcc Ser	taa *														441

Pro Al 1	a Leu	Pro	Glu 5	Asp	Gly	Gly	Ser	Gly 10	Ala	Phe	Pro	Pro	Gly 15	His
Phe Ly	s Asp	Pro 20	Lys	Arg	Leu	Tyr	Cys 25	Lys	Asn	Gly	Gly	Phe 30	Phe	Leu
Arg Il	e His	Pro	Asp	Gly	Arg	Val 40	Asp	Gly	Val	Arg	Glu 45	Lys	Ser	Asp
Pro Hi 50	s Ile	Lys	Leu	Gln	Leu 55	Gln	Ala	Glu	Glu	Arg 60	Gly	Val	Val	Ser
Ile Ly 65	s Gly	Val	Cys	Ala 70	Asn	Arg	Tyr	Leu	Ala 75	Met	Lys	Glu	Asp	Gly 80
Arg Le	ı Leu	Ala	Ser 85	Lys	Cys	Val	Thr	Asp 90	Glu	Cys	Phe	Phe	Phe 95	Glu
Arg Le	ı Glu	Ser 100	Asn	Asn	Tyr	Asn	Thr 105	Tyr	Arg	Ser	Arg	Lys 110	Tyr	Ser
Ser Tr	7 Tyr 115	Val	Ala	Leu	Lys	Arg 120	Thr	Gly	Gln	Tyr	Lys 125	Leu	Gly	Pro
Lys Th	_	Pro	Gly	Gln	Lys 135	Ala	Ile	Leu	Phe	Leu 140	Pro	Met	Ser	Ala
Lys Se 145	r													

	gcc Ala												4:	8
	aag Lys												9	6
	atc Ile												14	4
	cac His 50		_				_	_		_	 _		19:	2
	aaa Lys			_	_								24	0
_	tta Leu	-	_										28	8
	ttg Leu	_							~ ~				33	6
_	tgg Trp			_	_	-			_				38	4
	aca Thr 130												43	2
_	agc Ser	tga *											44	1

									cta Leu					48
		_							gat Asp					96
									cac His				1	144
									atc Ile 60				3	192
									gly aaa				2	240
_		_	_		_	_		_	cta Leu	_			2	288
_	_	_	_						gaa Glu				3	336
		_		_					 tat Tyr	_	_		3	384
									999 Gly 140				4	132
_		ttc Phe			_		_		taa *				4	468

	gca Ala															48
	agc Ser															96
	tgc Cys							_	_					 _	;	144
	gac Asp 50														;	192
	gca Ala															240
-	tac Tyr	_	_	_	_	_	_								:	288
_	acg Thr	_		_				-	_	_	_				;	336
	act Thr															384
	act Thr 130														,	432
_	ata Ile					_		_	_	_	tga *	ttt	taa			474

Primary Endpoint:

Relative Change in PWT at 90 days 1° Analysis: overall p = .075 (ANOVA) 2° Analysis: overall p = .035 (ANOVA of Ranks)

p = .026





FIGURE 6


Absolute Change in PWT



Change in PWT (minutes)

FIGURE 7

Change in PW % Absolute (



MJW - Jan 10 RJL-rev2 CONFIDENTIAL

Ankle Brachial Index at days 1, 90, 180




FIGURE 9

WIQ: Severity of Claudication





FIGURE 10

DOUBLE FIGURE 11 Walking Impairment Questionnaire SINGLE Severity Scores (%) Speed Baseline **■** Day 90 DOUBLE 30% 10% 20% % Stair Climbing ■ Baseline ■ Day 90 ■ Day 180 DOUBLE Placebo 40% 30% 50% 10% %0 SINGLE Distance Placebo + %0 30% 20% 10%



All PAD: Summary of Results

VARIABLE

Ibvolumeny overall

PWT: pairwise/geometric

Claudication Onset Time

Ankle Brachial Index

WIQ: claudication

WIQ: distance WIQ: speed

WIQ: stairs

SF-36: Physical Score

SF-36: Mental Score

Jay 90

Day 180

+/+++

-++=p<.05; ++=p<.15; +, 0, -=directional change relative to placebo

SINGLE / DOUBLE






FIGURE 15





FIGURE 16






FIGURE 20

Effect of Single Administration IA and IM vs. Continuous Infusion FGF-2 on Total Hindlimb Blood Flow in Rat Bilateral PAD Model

